IM. Issued U.S. patents cover SUMF1 compositions (set to expire in 2019), purified recombinant VIMIZIM compositions (set to expire in 2029) and methods of treating Morquio Syndrome (set to expire in 2029). The company also has issued the U.S. and the European patents that cover methods of production and are set to expire in 2024. Government Regulation The company’s products require approval from the Food and Drug Administration, the European Medicines Agency, and corresponding agencies in other countries before they could be marketed. History BioMarin Pharmaceutical Inc. was founded in 1996. The company was incorporated in Delaware in 1996 and began its operations in 1997.
biomarin pharmaceutical inc
770 Lindaro Street
San Rafael, CA 94901
|Alkermes PLC||$43.14 USD||-0.98|
|Dendreon Corp||$1.35 USD||-0.005|
|Jazz Pharmaceuticals PLC||$157.61 USD||-0.69|
|Spectrum Pharmaceuticals Inc||$7.51 USD||-0.24|
|Vertex Pharmaceuticals Inc||$88.99 USD||-2.31|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact BIOMARIN PHARMACEUTICAL INC, please visit www.biomarinpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.